GSK relaunches COPD.com

Share this article:
GSK relaunches COPD.com
GSK relaunches COPD.com

GlaxoSmithKline encouraged investors during its second-quarter earnings call to give the company some time to build momentum. The respiratory division was particularly hard hit (sales fell 14% during the quarter, 17% for the six-year mark), and as Bloomberg noted in June, new treatments Breo and Anoro have not swept the marketplace.

A refresh of its website COPD.com website appears to be asking patients what it asked investors — to give it a shot—albeit in an unbranded, indirect manner. 

The new look includes a more direct approach to exploring the site through revisions such as replacing the Understanding,” “Treating” and “Living” navigation bar with terms including “Be Inspired,” “Learn COPD Basics” and “Make a COPD Plan.”

It also includes what GSK's external communications director, Juan Carlos Molina, calls an effort to break the “dialogue barrier” that keeps patients from taking to their physicians, caregivers, friends and family about their lung disease. The key: the eight COPD patients and 40 bite-sized testimonials. GSK would not share the name of the agency that designed the site. [Update: GSK says Havas designed the site.]

Molina says the GSK team pre-relaunch research showed that first-person experiences really helped patients connect with the information. Like most unbranded sites the goal is to offer education and support. Molina says GSK's take on this was to use patients and language that “reflected the attitude of engagement with the disease,” so they could “feel a desire to learn about it,” and to provide clear, accessible information.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...